Drugs / Intravenous immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02404298 | Feb 2015 → Jan 2018 | autoimmune disorder of musculoskeletal system, chronic inflammatory demyelinating polyradiculoneuropathy | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous immunoglobulins | “Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP.” NCT02404298 ↗ |
| Known as | IVIg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02404298 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP.” NCT02404298 ↗ |
| Route | Intravenous | “Intravenous immunoglobulins (IVIg)” NCT02404298 ↗ |